Compare Invesco Ltd. (IVZ) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Twist Bioscience Corp — how do they compare? Invesco Ltd. trades at $29.51 (market cap $13.28B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Invesco Ltd. pays a 2.86% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and Twist Bioscience Corp for 27 Days on average.
| IVZ | TWST | |
|---|---|---|
Market Cap | $13.28B | $10.08B |
Volume | 3,698,033 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $33.31 | $205.00 |
52-Week Low | $22.44 | $25.45 |
Typical Hold Time | 77 Days | 27 Days |
Enterprise Value | $23.45B | $10.01B |
Dividend Yield | 2.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVZ trades at $30.09, down 1.34% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $281.70 million in 2025 despite revenue growth to $6.38 billion, though recent earnings beats in Q4 2025 and Q2 2026 show some operational resilience. Analyst consensus is mixed with a $33.14 price target, and the firm continues expanding its ETF suite, including the recent launch of the Invesco Nasdaq International Innovators 100 ETF.
The outlook remains cautious due to negative profitability margins and bearish technicals, but the absence of sell ratings and a dividend payment provide some support. Key risks include sustained negative net income and competitive pressures in the asset management sector, while potential upside hinges on improved earnings and AUM growth momentum.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
